Loading stock data…
Xencor, Inc. (XNCR)
$25.33-1.28 (-4.81%)
Market ClosedLast close Sep 8
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Xencor, Inc. in the Healthcare sector is trading at $25.33 with a market capitalization of $1.5B. Wall Street consensus targets $30.08 (12 analysts), implying a +18.8% move over the next 12 months. The stock is currently 17% below its 52-week high of $30.61, remaining 66.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +18.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $51.22M↑ | $4.52M↓ | $28.24M↑ | $21.00M↓ | $43.61M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$37.07M↑ | -$77.86M↓ | -$53.63M↓ | -$47.52M↓ | -$33.17M |
| Net Income | -$21.73M↑ | -$128.92M↓ | -$6.65M↓ | -$6.03M↑ | -$30.82M |
Peer Comparison
JNJUNHPFE
Fundamentals
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.55B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.84
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.46%
Volume
Today's trading volume
1.24M
Recent News
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor’s net loss widened to US$150.65 million and loss per share to US$1.99, highlighting a tension between short-term quarterly progress and heavier year-to-date spending. We’ll now consider how this quarterly...
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sector Update: Healthcare Stocks Mixed Late Afternoon
Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the